Do analysts rate ALDX or AIMD?

Aldeyra Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 213.39%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Aldeyra Therapeutics is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALDX or AIMD more profitable?

Aldeyra Therapeutics has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Aldeyra Therapeutics' return on equity of -57.34% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -57.34% -36.33% Ainos -11,912.10% -160.55% -62.29%

Does the media prefer ALDX or AIMD?

In the previous week, Aldeyra Therapeutics had 3 more articles in the media than Ainos. MarketBeat recorded 7 mentions for Aldeyra Therapeutics and 4 mentions for Ainos. Aldeyra Therapeutics' average media sentiment score of 0.16 beat Ainos' score of -0.19 indicating that Aldeyra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aldeyra Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ainos 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate AIMD or PEPG?

PepGen has a consensus target price of $11.60, indicating a potential upside of 702.77%. Given PepGen's stronger consensus rating and higher probable upside, analysts clearly believe PepGen is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PepGen 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has higher valuation and earnings, AIMD or PEPG?

Ainos has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ainos $120K 151.66 -$14.77M -$2.89 N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is AIMD or PEPG more profitable?

PepGen has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. PepGen's return on equity of -59.89% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Ainos -11,912.10% -160.55% -62.29% PepGen N/A -59.89% -49.62%

Does the media refer more to AIMD or PEPG?

In the previous week, Ainos had 2 more articles in the media than PepGen. MarketBeat recorded 4 mentions for Ainos and 2 mentions for PepGen. PepGen's average media sentiment score of 0.51 beat Ainos' score of -0.19 indicating that PepGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ainos 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PepGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AIMD or VRCA?

Verrica Pharmaceuticals has a consensus price target of $14.50, indicating a potential upside of 141.47%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Verrica Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is AIMD or VRCA more profitable?

Verrica Pharmaceuticals has a net margin of -47.97% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -160.55% beat Verrica Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Ainos -11,912.10% -160.55% -62.29% Verrica Pharmaceuticals -47.97% -1,077.78% -40.76%

Does the media refer more to AIMD or VRCA?

In the previous week, Ainos had 3 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 4 mentions for Ainos and 1 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.63 beat Ainos' score of -0.19 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ainos 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PYXS or AIMD?

Pyxis Oncology presently has a consensus target price of $6.83, indicating a potential upside of 300.78%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Pyxis Oncology is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PYXS or AIMD more profitable?

Pyxis Oncology has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Pyxis Oncology's return on equity of -135.60% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% Ainos -11,912.10% -160.55% -62.29%

Does the media refer more to PYXS or AIMD?

In the previous week, Ainos had 3 more articles in the media than Pyxis Oncology. MarketBeat recorded 4 mentions for Ainos and 1 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.94 beat Ainos' score of -0.19 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ainos 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend AIMD or BMEA?

Biomea Fusion has a consensus price target of $8.50, indicating a potential upside of 522.71%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biomea Fusion 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has better valuation and earnings, AIMD or BMEA?

Ainos has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ainos $120K 151.66 -$14.77M -$2.89 N/A Biomea Fusion N/A N/A -$61.80M -$0.68 N/A

Is AIMD or BMEA more profitable?

Biomea Fusion has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -160.55% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Ainos -11,912.10% -160.55% -62.29% Biomea Fusion N/A -265.37% -103.96%

Does the media favor AIMD or BMEA?

In the previous week, Ainos had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 4 mentions for Ainos and 2 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.62 beat Ainos' score of -0.19 indicating that Biomea Fusion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ainos 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ainos (AIMD) Competitors

$2.14 -0.06 (-2.91%)

As of 01:52 PM Eastern

Compare

AIMD vs. ALDX, PEPG, VRCA, PYXS, and BMEA

Should you buy Ainos stock or one of its competitors? MarketBeat compares Ainos with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ainos include Aldeyra Therapeutics (ALDX), PepGen (PEPG), Verrica Pharmaceuticals (VRCA), Pyxis Oncology (PYXS), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry.

How does Ainos compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Ainos has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Ainos	$120K	151.66	-$14.77M	-$2.89	N/A

Aldeyra Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 213.39%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Aldeyra Therapeutics is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Aldeyra Therapeutics had 3 more articles in the media than Ainos. MarketBeat recorded 7 mentions for Aldeyra Therapeutics and 4 mentions for Ainos. Aldeyra Therapeutics' average media sentiment score of 0.16 beat Ainos' score of -0.19 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ainos	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aldeyra Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Ainos has a beta of 2.41, meaning that its share price is 141% more volatile than the broader market.

Aldeyra Therapeutics has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Aldeyra Therapeutics' return on equity of -57.34% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
Ainos	-11,912.10%	-160.55%	-62.29%

59.7% of Aldeyra Therapeutics shares are held by institutional investors. 11.8% of Aldeyra Therapeutics shares are held by insiders. Comparatively, 9.8% of Ainos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Aldeyra Therapeutics beats Ainos on 11 of the 15 factors compared between the two stocks.

How does Ainos compare to PepGen?

Ainos (NASDAQ:AIMD) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

PepGen has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. PepGen's return on equity of -59.89% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-160.55%	-62.29%
PepGen	N/A	-59.89%	-49.62%

Ainos has a beta of 2.41, suggesting that its share price is 141% more volatile than the broader market. Comparatively, PepGen has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market.

PepGen has a consensus target price of $11.60, indicating a potential upside of 702.77%. Given PepGen's stronger consensus rating and higher probable upside, analysts clearly believe PepGen is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

58.0% of PepGen shares are held by institutional investors. 9.8% of Ainos shares are held by company insiders. Comparatively, 1.3% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Ainos has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120K	151.66	-$14.77M	-$2.89	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

In the previous week, Ainos had 2 more articles in the media than PepGen. MarketBeat recorded 4 mentions for Ainos and 2 mentions for PepGen. PepGen's average media sentiment score of 0.51 beat Ainos' score of -0.19 indicating that PepGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ainos	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PepGen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PepGen beats Ainos on 9 of the 15 factors compared between the two stocks.

How does Ainos compare to Verrica Pharmaceuticals?

Ainos (NASDAQ:AIMD) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Ainos has a beta of 2.41, suggesting that its share price is 141% more volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Ainos has higher earnings, but lower revenue than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120K	151.66	-$14.77M	-$2.89	N/A
Verrica Pharmaceuticals	$35.58M	2.90	-$17.89M	-$1.03	N/A

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 9.8% of Ainos shares are held by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Ainos had 3 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 4 mentions for Ainos and 1 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.63 beat Ainos' score of -0.19 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ainos	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Verrica Pharmaceuticals has a consensus price target of $14.50, indicating a potential upside of 141.47%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Verrica Pharmaceuticals has a net margin of -47.97% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -160.55% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-160.55%	-62.29%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

Summary

Verrica Pharmaceuticals beats Ainos on 10 of the 16 factors compared between the two stocks.

How does Ainos compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

In the previous week, Ainos had 3 more articles in the media than Pyxis Oncology. MarketBeat recorded 4 mentions for Ainos and 1 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.94 beat Ainos' score of -0.19 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ainos	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

39.1% of Pyxis Oncology shares are held by institutional investors. 10.6% of Pyxis Oncology shares are held by company insiders. Comparatively, 9.8% of Ainos shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Pyxis Oncology has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, Ainos has a beta of 2.41, suggesting that its stock price is 141% more volatile than the broader market.

Pyxis Oncology has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Pyxis Oncology's return on equity of -135.60% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Ainos	-11,912.10%	-160.55%	-62.29%

Pyxis Oncology presently has a consensus target price of $6.83, indicating a potential upside of 300.78%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Pyxis Oncology is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Ainos has lower revenue, but higher earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	7.79	-$79.62M	-$1.31	N/A
Ainos	$120K	151.66	-$14.77M	-$2.89	N/A

Summary

Pyxis Oncology beats Ainos on 10 of the 16 factors compared between the two stocks.

How does Ainos compare to Biomea Fusion?

Ainos (NASDAQ:AIMD) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Biomea Fusion has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -160.55% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-160.55%	-62.29%
Biomea Fusion	N/A	-265.37%	-103.96%

Ainos has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120K	151.66	-$14.77M	-$2.89	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

Ainos has a beta of 2.41, indicating that its stock price is 141% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, indicating that its stock price is 131% less volatile than the broader market.

Biomea Fusion has a consensus price target of $8.50, indicating a potential upside of 522.71%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Ainos had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 4 mentions for Ainos and 2 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.62 beat Ainos' score of -0.19 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ainos	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.7% of Biomea Fusion shares are owned by institutional investors. 9.8% of Ainos shares are owned by company insiders. Comparatively, 10.6% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Biomea Fusion beats Ainos on 8 of the 15 factors compared between the two stocks.

Get Ainos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIMD vs. The Competition

Export

Metric	Ainos	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.20M	$2.97B	$6.43B	$12.45B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-0.74	18.10	23.85	24.37
Price / Sales	151.66	306.21	522.03	117.40
Price / Cash	N/A	55.72	41.27	57.13
Price / Book	1.66	3.94	10.04	6.75
Net Income	-$14.77M	$75.85M	$3.56B	$337.03M
7 Day Performance	-22.04%	-1.56%	-0.82%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.66%
1 Year Performance	-34.28%	23.11%	28.88%	34.01%

Ainos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIMD Ainos	0.3452 of 5 stars	$2.14 -2.9%	N/A	-31.7%	$18.20M	$120K	N/A	40	News Coverage Gap Down
ALDX Aldeyra Therapeutics	3.3148 of 5 stars	$1.71 -3.9%	$5.50 +221.6%	-20.9%	$107.37M	N/A	N/A	10
PEPG PepGen	2.8181 of 5 stars	$1.52 -0.7%	$11.60 +663.2%	-7.2%	$105.83M	N/A	N/A	30	Negative News Analyst Downgrade
VRCA Verrica Pharmaceuticals	2.7899 of 5 stars	$6.06 +0.7%	$14.50 +139.3%	+10.5%	$103.42M	$35.58M	N/A	40
PYXS Pyxis Oncology	3.8683 of 5 stars	$1.73 +6.1%	$6.83 +295.0%	+28.8%	$103.27M	$13.86M	N/A	60	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIMD) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ainos (AIMD) Competitors

AIMD vs. ALDX, PEPG, VRCA, PYXS, and BMEA

How does Ainos compare to Aldeyra Therapeutics?

Summary

How does Ainos compare to PepGen?

Summary

How does Ainos compare to Verrica Pharmaceuticals?

Summary

How does Ainos compare to Pyxis Oncology?

Summary

How does Ainos compare to Biomea Fusion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIMD vs. The Competition

Ainos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ainos (AIMD) Competitors

AIMD vs. ALDX, PEPG, VRCA, PYXS, and BMEA

How does Ainos compare to Aldeyra Therapeutics?

Which has higher valuation and earnings, ALDX or AIMD?

Do analysts rate ALDX or AIMD?

Does the media prefer ALDX or AIMD?

Which has more risk and volatility, ALDX or AIMD?

Is ALDX or AIMD more profitable?

Do institutionals & insiders have more ownership in ALDX or AIMD?

Summary

How does Ainos compare to PepGen?

Is AIMD or PEPG more profitable?

Which has more risk & volatility, AIMD or PEPG?

Do analysts rate AIMD or PEPG?

Do institutionals and insiders have more ownership in AIMD or PEPG?

Which has higher valuation and earnings, AIMD or PEPG?

Does the media refer more to AIMD or PEPG?

Summary

How does Ainos compare to Verrica Pharmaceuticals?

Which has more volatility & risk, AIMD or VRCA?

Which has preferable earnings & valuation, AIMD or VRCA?

Do insiders and institutionals have more ownership in AIMD or VRCA?

Does the media refer more to AIMD or VRCA?

Do analysts recommend AIMD or VRCA?

Is AIMD or VRCA more profitable?

Summary

How does Ainos compare to Pyxis Oncology?

Does the media refer more to PYXS or AIMD?

Do insiders & institutionals have more ownership in PYXS or AIMD?

Which has more volatility and risk, PYXS or AIMD?

Is PYXS or AIMD more profitable?

Do analysts recommend PYXS or AIMD?

Which has stronger earnings and valuation, PYXS or AIMD?

Summary

How does Ainos compare to Biomea Fusion?

Is AIMD or BMEA more profitable?

Which has better valuation and earnings, AIMD or BMEA?

Which has more risk and volatility, AIMD or BMEA?

Do analysts recommend AIMD or BMEA?

Does the media favor AIMD or BMEA?

Do insiders & institutionals believe in AIMD or BMEA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIMD vs. The Competition

Ainos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools